Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Dopaminergic Modulation of CD4+CD25 Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-β Therapy.
The extent of ultrastructural spinal cord pathology reflects disease severity in experimental autoimmune encephalomyelitis.
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Cranial neuropathies in multiple sclerosis defined by magnetic resonance imaging and fludeoxyglucose f 18 positron emission tomography.
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.

Pages